Literature DB >> 8023064

[Creutzfeldt-Jakob disease after treatment with human extracted growth hormone. A clinicopathological study].

M B Delisle1, N Fabre, P Rochiccioli, J Doerr-Schott, J L Rumeau, A Bes.   

Abstract

This report describes the pathological changes observed in the brain of a 18-year-old patient who died with Creutzfeldt-Jakob disease (CJD) of the ataxic and panencephalopathic type. Clinically, the disease began at age 17 with a rapidly progressive cerebellar syndrome, associated with myoclonus and mental deterioration. Cranial CT scan and MRI showed minor abnormalities. EEG demonstrated non specific changes. The patient became progressively demented, bedridden and died 10 months after the onset. Nine years earlier, he had been operated upon for craniopharyngioma and subsequently treated with cadaver-derived human growth hormone. Post-mortem examination of the brain revealed mild diffuse atrophy. Histology showed congophilic amyloid plaques found in both gray and white matters of the cerebrum and cerebellum, associated with spongiosis, mainly in the basal ganglia and cerebellum, and gliosis. They were immunostained with antiprion protein antibody using the immunoperoxidase method on paraffin embedded sections. The clinical findings in this case were similar to those of other cases of human growth hormone-associated CJD. However, this case is unusual because of the great number of amyloid plaques, which have been only rarely found in previous reports.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8023064

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  5 in total

1.  Transmission properties of atypical Creutzfeldt-Jakob disease: a clue to disease etiology?

Authors:  Atsushi Kobayashi; Piero Parchi; Masahito Yamada; Paul Brown; Daniela Saverioni; Yuichi Matsuura; Atsuko Takeuchi; Shirou Mohri; Tetsuyuki Kitamoto
Journal:  J Virol       Date:  2015-01-21       Impact factor: 5.103

Review 2.  Prion protein scrapie and the normal cellular prion protein.

Authors:  Caroline J Atkinson; Kai Zhang; Alan L Munn; Adrian Wiegmans; Ming Q Wei
Journal:  Prion       Date:  2016       Impact factor: 3.931

3.  MRI and clinical syndrome in dura mater-related Creutzfeldt-Jakob disease.

Authors:  B Meissner; K Kallenberg; P Sanchez-Juan; S Ramljak; A Krasnianski; U Heinemann; S Eigenbrod; E Gelpi; B Barsic; H A Kretzschmar; W J Schulz-Schaeffer; M Knauth; I Zerr
Journal:  J Neurol       Date:  2009-01-23       Impact factor: 4.849

4.  Distinct pathological phenotypes of Creutzfeldt-Jakob disease in recipients of prion-contaminated growth hormone.

Authors:  Ignazio Cali; Cathleen J Miller; Joseph E Parisi; Michael D Geschwind; Pierluigi Gambetti; Lawrence B Schonberger
Journal:  Acta Neuropathol Commun       Date:  2015-06-25       Impact factor: 7.801

5.  Comparative Study of Prions in Iatrogenic and Sporadic Creutzfeldt-Jakob Disease.

Authors:  Xiangzhu Xiao; Jue Yuan; Liuting Qing; Ignazio Cali; Jacqueline Mikol; Marie-Bernadette Delisle; Emmanuelle Uro-Coste; Liang Zeng; Mai Abouelsaad; Dimitris Gazgalis; Manuel Camacho Martinez; Gong-Xian Wang; Paul Brown; James W Ironside; Pierluigi Gambetti; Qingzhong Kong; Wen-Quan Zou
Journal:  J Clin Cell Immunol       Date:  2014-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.